Development of designed site-directed pseudopeptide-peptido-mimetic immunogens as novel minimal subunit-vaccine candidates for malaria

Molecules

Volumn 15, Issue 12, 2010, Pages 8856-8889

  Lozano, José Manuel ^a   Lesmes, Liliana P ^a   Carreno, Luisa F ^a   Gallego, Gina M ^a   Patarroyo, Manuel Elkin ^a  

^a UNIVERSIDAD DEL ROSARIO   (Colombia)

Author keywords

Ig passive transferring; Malaria vaccine; Peptide high binding motif; Peptide bond isoster; Pseudopeptide; Transition state analogue

Indexed keywords

MALARIA VACCINE; PEPTIDOMIMETIC AGENT; RECOMBINANT VACCINE; SUBUNIT VACCINE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CHEMISTRY; HAPLORHINI; HUMAN; IMMUNOLOGY; MALARIA FALCIPARUM; MOUSE; SYNTHESIS;

ANIMALS; HAPLORHINI; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; MICE; MICE, INBRED BALB C; PEPTIDOMIMETICS; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 78650670592     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules15128856     Document Type: Article

References (81)

1. Dellicour. S.; Tatem, A.J.; Guerra, C.A.; Snow, R.W.; ter Kuile, F.O. Quantifying the Number of Pregnancies at Risk of Malaria in 2007. A Demographic Study. PLoS Med. 2010, 7, e1000221. doi:10.1371/journal.pmed.1000221
2. Graves, P.; Gelband, H.; Garne, P. The SPf66 malaria vaccine: what is the evidence for efficacy? Parasitol. Today 1998, 14, 219.
3. Patarroyo, M.E.; Romero, P.; Torres, M.L.; Clavijo, P.; Moreno, A.; Martínez, A.; Rodríguez, R.; Guzmán, F.; Cabezas, E. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature 1987, 328, 629-632.
4. Patarroyo, M.E.; Amador, R.; Clavijo, P.; Moreno, A.; Guzmán, F.; Romero, P.; Tascón, R.; Franco, A.; Murillo, L.; Pontón, G.; Trujillo, G. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 1988, 332, 158-161.
5. Miller, L.H.; Good, M.F.; Kaslow, D.C. Vaccines against the blood stages of Falciparum malaria. Adv. Exp. Med. Biol. 1998, 452, 193-205.
6. Holder, A.; Lockyer, M.J.; Odink, K.G.; Sandhu, J.S.; Riveros, M.V.; Davey, L.S.; Tizard, M.L.V.; Schwarz, R.T.; Freeman, R.R. Primary structure of the precursor to the three major surface antigens of plasmodium falciparum merozoites. Nature 1985, 317, 270-273.
7. Tanabe, K.; Makay, M.; Goman, M.; Scaife, J.G. Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparum. J. Mol. Biol. 1987, 195: 273-287.
8. Fenton, B.; Clark, J.T.; Khan, C.M.; Robinson, J.V.; Walliker, D.; Ridley, R. Structural and antigenic polymorphism of the 35- to 48-kilodalton merozoite surface antigen (MSA-2) of the malaria parasite Plasmodium falciparum. Mol. Cell Biol. 1991, 11, 963-971.
9. Lerner, R.A.; Benkovic, S.J.; Schultz, P.G. At the crossroads of chemistry and immunology: catalytic antibodies. Science 1991, 252, 659-667.
10. Li, K.; Foy, E.; Ferreon, J.C.; Nakamura, M.; Ferreon, A.C.; Ikeda, M.; Ray, S.C.; Gale, M.; Lemon, S.M. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl. Acad. Sci. USA 2005, 102, 2992-2997.
11. Kontogiorgis, C.A.; Papaioannou, P.; Hadjipavlou-Litina, D.J. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results. Curr. Med. Chem. 2005, 12, 339-355.
12. Spatola, A.F. Chemistry and Biochemistry of Amino acids, Peptides and Proteins; Weinstein, B., Ed.; Marcel Dekker Inc.: New York, NY, USA, 1983; volume 7, pp. 267-357.
13. Sefler, A.M.;He, J.X.; Sawyer, T.K.; Holub, K.E.; Omecinsky, D.O.; Reily, M.D.; Thanabal, V.; Akunne, H.C.; Cody, W.L. Design and structure-activity relationships of C-terminal cyclic neurotensin fragment analogues. J. Med. Chem. 1995, 38, 249-257.
14. Guichard, G. Pseudopeptides in Drug Development; Nielsen, P.E., Ed.; Wiley-VCH: Weinheim, Germany, 2004; pp. 33-120.
15. Kritzer, J.A.; Stephens, O.M.; Guarracino, D.A.; Reznik, S.K.; Schepartz, A. β-Peptides as inhibitors of protein-protein interactions. Bioorg. Med. Chem. 2005, 13, 11-16.
16. Fischer, L.; Didierjean, C.; Jolibois, F.; Semetey, V.; Lozano, J.M.; Briand, J.P.; Marraud, M.; Poteau, R.; Guichard, G. Propensity for local folding induced by the urea fragment in short-chain Oligomers. Org. Biomol. Chem. 2008, 6, 2596-2610.
17. 2NH peptide bond isostere. Peptides 1987, 1, 119-121.
18. 2NH] pseudopeptide analogues of a highly potent somatostatin octapeptide. J. Med. Chem. 1987, 30, 1162-1166.
19. Kamphuis, I.G.; Drenth, J.; Baker, E.N. Thiol proteases. Comparative studies based on the highresolution structures of papain and actinidin, and on amino acid sequence information for cathepsins B and H, and stem bromelain. J. Mol. Biol. 1985, 182, 317-329.
20. Chorev, M.; Goodman, M. Recent developments in retro peptides and proteins - an ongoing topochemical exploration. Trends Biotechnol. 1995, 13, 438-45.
21. Bastian, M.; Lozano, J.M.; Patarroyo, M.E.; Pluschke, G.; Daubenberger, C.A. Characterization of a reduced peptide bond analogue of a promiscuos CD4 T cell epitope derived from the Plasmodium falciparum malaria vaccine candidate merozoite surface protein 1. Mol. Immunol. 2004, 41, 775-784.
22. Merrifield, R.B.; Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J. Am. Chem. Soc. 1963, 85, 2149.
23. Houghten, R.A. General method for the rapid solid-phase peptide synthesis of the large number of peptides: specificity of antigenantibody interactions of the level of individual amino acids. Proc. Natl. Acad. Sci. USA 1985, 82, 5131.
24. Guichard, G. Solid-Phase Synthesis; Kates, S., Albericio, F., Eds.; Marcel Dekker: New York, NY, USA, 2000; pp. 649-703.
25. Kruijzer, J.A.W.; Lefeber, D.J.; Liskamp, R.M.J. Approaches to the Synthesis of Ureapeptoid Peptidomimetics. Tetrahedron Lett. 1997, 38, 5335-5338.
26. Mardsen, A.F.; Caffrey, P.; Aparicio, J.F.; Loughran, M.S.; Staunton, J.; Leadlay, P.F. Stereospecific Acyl Transfers on the Erythromycin-Producing Polyketide Synthase. Science 1994, 263, 380-384.
27. Du, X.; Hansell, E.; Engel, J.C.; Caffrey, C.R.; Cohen, F.E.; McKerrow, J.H. Aryl ureas represent a new class of anti-trypanosomal agents. Chem. Biol. 2000, 7, 733-742.
28. Kozikowski, A.P.; Zhang, J.; Nan, F.; Petukhov, P.A.; Grajkowska, E.; Wroblewski, J.T.; Yamamoto, T.; Bzdega, T.; Wroblewska, B.; Neale, J.H. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J. Med. Chem. 2004, 47, 1729-1738.
29. Dannecker, W.; Kopf, J.; Rust, H. N,N'-Diphenylurea, C13H12N20. Cryst. Struct. Commun. 1979, 8, 429.
30. Ranganathan, D.; Kurur, S.; Madhusudanan, K.P.; Karle, I.L. Self-assembling Urea-based Peptidomimetics: A Simple One-step Synthesis and Crystal Structure of Core b-Alanyl Ureylene Retro-bispeptides (MeO-Aaa-[NH-CO-NH]-CH2-CH2-CO-NH-Aaa-OMe; Aaa= amino acid A). Tetrahedron Lett. 1997, 38, 4659-4662.
31. Semetey, V.; Didierjean, C.; Briand, J.P.; Aubry, A.; Guichard, G. Stable helical secondary structure in short chain N,N'-linked oligoureas bearing proteinogenic side chains. Angew. Chem. Int. Ed. 2002, 41, 1895-1898.
32. Nowick, J.S. Chemical models of protein b-sheets. Acc. Chem. Res. 1999, 32, 287-296.
33. Violette, A.; Averlant-Petit, M.C.; Semetey, V.; Hemmerlin, C.; Casimir, R.; Graff, R.; Marraud, M.; Briand, J.P.; Rognan, D.; Guichard, G. N,N'-Linked Olgoureas as foldamers: Chain Length requirements for helix formation in protic solvent investigated by circular dichroism, NMR spectroscopy and molecular dynamics. J. Am. Chem. Soc. 2005, 127, 2156-2164.
34. Violette, A.; Fournel, S.; Lamour, K.; Chaloin, O.; Frisch, B.; Briand, J.P.; Monteil, H.; Guichard, G. Mimicking Helical Antibacterial Peptides with Nonpeptidic Folding Oligomers. Chem. Biol. 2006, 13, 531-538.
35. Tritsch, G.L.; Wooley, D.W. The Synthesis of L-Leucyl-L-valyl-L- cysteinylglycyl-L-glutyl- Larginine, an Insulin Fragment with Strepogenin Activity. J. Am. Chem. Soc. 1960, 82, 2787-2793.
36. Vegner, R.E.; Chipens, G.I.; Kibirev, V.K. Synthesis of [1-(ethyl ester of carbonylglycine), 2-Darginine, 5-valine]-angiotensin II and [1-carbon-ylglycinamide, 2-D-arginine, 5-valine]- angiotensin II. Chem. Nat. Compd. 1975, 9, 481-484.
37. Kawasaki, K.; Maeda, M.; Watanabe, J.; Kaneto, H. Amino acids and peptides IX. Synthetic studies on Le-enkephalin analogues containing a ureylene bond. Chem. Pharm. Bull. 1988, 36, 1766-1771.
38. Rodriguez, M.; Dubreuil, P.; Bali, J.P.; Martinez, J. Synthesis and biological activity of partially modified retro-inverso pseudopeptide derivatives of the C-terminal tetrapeptide of gastrin. J. Med. Chem. 1987, 30, 758-763.
39. Myers, A.C.; Kowalski, J.A.; Lipton, M.A. Facile incorporation of urea pseudopeptides into protease substrate analogue inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 5219-5222.
40. Guerlavais, V.; Boeglin, D.; Mousseaux, D.; Oiry, C.; Heitz, A.; Deghenghi, R.; Locatelli, V.; Torsello, A.; Ghe, C.; Catapano, F.; Muccioli, G.; Galleyrand, J.C.; Fehrentz, J.A.; Martinez, J. New active series of growth hormone secretagogue. J. Med. Chem. 2003, 46, 1191-1203.
41. Mishnev, A.F.; Bleidelis, Y.Y.; Liepin'sh, E.E.; Ramzaeva, N.P.; Goncharova, I.N. Synthesis and structure of 6-substituted 9-(2-ethoxy-1,3- dioxan-5-yl)purines. Chem. Heterocycl. Compd. 1979, 15, 798-804.
42. Semetey, V.; Hemmerlin, C.; Didierjean, C.; Schaffner, A.P.; Giner, A.G.; Aubry, A.; Briand, J.P.; Marraud, M.; Guichard, G. Unexpected stability of the urea cis-trans isomer in urea containing model pseudopeptides. Org. Lett. 2001, 3, 3843-3846.
43. Sureshbabu, V.V.; Patil, B.S.; Venkataramanarao, R. Preparation, isolation, and characterization of Nalpha-Fmoc-peptide isocyanates: solution synthesis of oligo-alpha-peptidyl ureas. J. Org. Chem. 2006, 71, 7697-7705.
44. Valmori, D.; Fonteneau, J.F.; Lizana, C.; Gervois, N.; Lienard, D.; Rimoldi, D.; Jongeneel, V.; Jotereau, F.; Cerottini, J.C.; Romero, P. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 1998, 160, 1750-1758.
45. Neimark, J.; Briand, J.P. Development of a fully automated multichannel peptide synthesizer with integrated TFA cleavage capability. J. Pept. Res. 1993, 6, 219-228.
46. Fischer, L.; Semetey, V.; Lozano, J.M.; Schaffner, A.P.; Briand, J.P.; Didierjean, C.; Guichard, G. Succinimidyl Carbamate Derivatives from N-Protected a-Amino Acids and Dipeptides-Synthesis of Ureidopeptides and Oligourea/Peptide Hybrids. Eur. J. Org. Chem. 2007, 2511-2525.
47. Altomare, M.C.; Burla, M.; Camalli, G.; Cascarano, C.; Giacovazzo, A.; Guagliardi, G.; Polidori, G. SIR92 - a program for automatic solution of crystal structures by direct methods J. Appl. Crystallogr. 1994, 27, 435-436.
48. Loudon, G.M.; Almond, M.R.; Jacob, J.N. The mechanism of hydrolysisof N-(1-Aminoalkyl) Amides. J. Am. Chem. Soc. 1981, 103, 4508-4515.
49. Ostankovitch, M.; Guichard, G.; Connan, F.; Muller, S.; Chaboissier, A.; Hoebeke, J.; Choppin, J.; Briand, J.P.; Guillet, J.G. A partially modified retro-inverso pseudopeptide modulates the cytokine profile of CTL specific for an influenza virus epitope. J. Immunol. 1998, 161, 200-208.
50. Albo, F.; Cavazza, A.; Giardina, B.; Lippa, S.; Marini, M.; Roda, L.G.; Spagnoli, G. Degradation of the immunogenic peptide gp100 (280-288) by the monocyte-like U937 cell line. Peptides 2003, 24, 371-378.
51. Lozano, J.M.; Espejo, F.; Diaz, D.; Salazar, L.M.; Rodriguez, J.; Pinzon, C.; Calvo, J.C.; Guzman, F.; Patarroyo, M.E. Reduced amide pseudopeptide analogues of a malaria peptide possess secondary structural elements responsible for induction of functional antibodies which react with native proteins expressed in Plasmodium falciparum erythrocyte stages. J. Pept. Res. 1998, 52, 457-469.
52. Lozano, J.M.; Alba, M.P.; Vanegas, M.; Silva, Y.; Torres-Castellanos, J.L.; Patarroyo, M.E. MSP- 1 malaria pseudopeptide analogs: biological and immunological significance and threedimensional structure. Biol. Chem. 2003, 384, 71-82.
53. Holder, A.A.; Blackman, M.J. What is the function of MSP-1 on the malaria merozoite? Parasitol. Today 1994, 10, 182-184.
54. Carvalho, L.J.; Daniel-Ribeiro, C.T.; Goto, H. Malaria vaccine: candidate antigens, mechanisms, constraints and prospects. Scand. J. Immunol. 2002, 56, 327-343.
55. Cheung, A.; Leban, J.; Shaw, A.R.; Merkli, B.; Stocker, J.; Chizzolini, C.; Sander, C.; Perrin, L.H. Immunization with synthetic peptides of a Plasmodium falciparum surface antigen induces antimerozoite antibodies. Proc. Natl. Acad. Sci. USA 1986, 83, 8328-8332.
56. Daubenberger, C.A.; Nickel, B.; Ciatto, C.; Grutter, M.G.; Poltl-Frank, F.; Rossi, L.; Siegler, U.; Robinson, J.; Kashala, O.; Patarroyo, M.E.; Pluschke, G. Amino acid dimorphism and parasite immune evasion: cellular immune responses to a promiscuous epitope of Plasmodium falciparum merozoite surface protein 1 displaying dimorphic amino acid polymorphism are highly constrained. Eur. J. Immunol. 2002, 32, 3667-3677.
57. Panina-Bordignon, P.; Tan, A.; Termijtelen, A.; Demotz, S.; Corradin, G.; Lanzavecchia, A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 1989, 19, 2237-2242.
58. Kashala, O.; Amador, R.; Valero, M.V.; Moreno, A.; Barbosa, A.; Nickel, B.; Daubenberger, C.A.; Guzman, F.; Pluschke, G.; Patarroyo, M.E. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine 2002, 20, 2263-2277.
59. Rotzschke, O.; Falk, K.; Mack, J.; Lau, J.M.; Jung, G.; Strominger, J.L. Conformational variants of class II MHC/peptide complexes induced by N- and C-terminal extensions of minimal peptide epitopes. Proc. Natl. Acad. Sci. USA 1999, 96, 7445-7450.
60. Sant'Angelo, D.B.; Robinson, E.; Janeway, C.A., Jr.; Denzin, L.K. Recognition of core and flanking amino acids of MHC class II-bound peptides by the T cell receptor. Eur. J. Immunol. 2002, 32, 2510-2520.
61. Wang, J.H.; Reinherz, E.L. Structural basis of T cell recognition of peptides bound to MHC molecules. Mol. Immunol. 2002, 38, 1039-1049.
62. Van Der Merwe, P.A.; Davis, S.J. Molecular interactions mediating T cell antigen recognition. Annu. Rev. Immunol. 2003, 21, 659-684.
63. Stemmer, C.; Quesnel, A.; Prevost-Blondel, A.; Zimmermann, C.; Muller, S.; Briand, J.P.; Pircher, H. Protection against lymphocytic choriomeningitis virus infection induced by a reduced peptide bond analogue of the H-2Db-restricted CD8(+) T cell epitope GP33. J. Biol. Chem. 1999, 274, 5550-5556.
64. Calbo, S.; Guichard, G.; Muller, S.; Kourilsky, P.; Briand, J.P.; Abastado, J.P. Antitumor vaccination using a major histocompatibility complex (MHC) class I-restricted pseudopeptide with reduced peptide bond. J. Immunother. 2000, 23, 125-130.
65. Levitsky, V.; Zhang, Q.J.; Levitskaya, J.; Masucci, M.G. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4a. J. Exp. Med. 1996, 183, 915-926.
66. Helg, A.; Mueller, M.S.; Joss, A.; Poltl-Frank, F.; Stuart, F.; Robinson, J.A.; Pluschke, G. Comparison of analytical methods for the evaluation of antibody responses against epitopes of polymorphic protein antigens. J. Immunol. Method. 2003, 276, 19-31.
67. Herrera, S.; Perlaza, B.L.; Bonelo, A.; Arevalo-Herrera, M. Aotus monkeys: their great value for anti-malaria vaccines and drug testing. Int. J. Parasitol. 2002, 32, 1625-1635.
68. Stowers, A.W.; Miller, L.H. Are trials in New World monkeys on the critical path for blood-stage malaria vaccine development? Trends Parasitol. 2001, 17, 415-419.
69. Lyon, J.A.; Haynes, J.D.; Diggs, C.L.; Chulay, J.D.; Haidaris, C.G.; Pratt-Rossiter, J. Monoclonal antibody characterization of the 195-kDa major surface glycoprotein of Plasmodium falciparum malaria schizonts and merozoites: identification of additional processed products and a serotyperestricted repetitive epitope. J. Immunol. 1987, 138, 895-901.
70. Pfeiffer, B.; Peduzzi, E.; Moehle, K.; Zurbriggen, R.; Gluck, R.; Pluschke, G.; Robinson, J.A. A virosome-mimotope approach to synthetic vaccine design and optimization: synthesis, conformation, and immune recognition of a potential malaria-vaccine candidate. Angew. Chem. Int. Ed. Engl. 2003, 42, 2368-2371.
71. Cubillos, M.; Espejo, F.; Purmova, J.; Martinez, J.C.; Patarroyo, M.E. Alpha helix shortening in 1522 MSP-1 conserved peptide analogues is associated with immunogenicity and protection against Plasmodium falciparum malaria. Proteins 2003, 50, 400-409.
72. Espejo, F.; Cubillos, M.; Salazar, L.M.; Guzmán, F.; Urquiza, M.; Ocampo, M.; Silva, Y.; Rodríguez, R.; Lioy, E.; Patarroyo, M.E. Structure, immunogenicity, and protectivity relationship for the 1585 malarial peptide and its substitution analogues. Angew. Chem. Int. Ed. 2001, 40, 4654-4657.
73. Lioy, E.; Suarez, J.; Guzmán, F.; Siegrist, S.; Pluschke, G.; Patarroyo, M.E. Synthesis, Biological, and Immunological Properties of Cyclic Peptides from Plasmodium falciparum Merozoite Surface Protein-1. Angew. Chem. Int. Ed. 2001, 40, 2631-2635.
74. Stern, L.J.; Brown, J.H.; Jardetzky, T.S.; Gorga, J.C.; Urban, R.G.; Strominger, J.L.; Wiley, D.C. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994, 368, 215-221.
75. Sloan-Lancaster, J.; Allen, P. Significance of T-cell stimulation by altered peptide ligands in T cell biology. Curr. Opin. Immunol. 1995, 7, 103-109.
76. Ghosh, P.; Amaya, M.; Mellins, E.; Wiley, D.C. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995, 378, 457-462.
77. Dessen, A.; Lawrence, C.M.; Cupo, S.; Zaller, D.M.; Wiley, D.C. X-ray crystal structure of HLADR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 1997, 7, 473-481.
78. Suárez, C.F.; Patarroyo, M.E.; Trujillo, E.; Estupiñá n, M; Baquero, J.E.; Parra, C.; Rodriguez, R. Owl monkey MHC-DRB exon 2 reveals high similarity with several HLA-DRB lineages. Immunogenetics 2006, 58, 542-558.
79. Thomas, A.W.; Carr, D.A.; Carter, J.M.; Lyon, J.A. Sequence comparison of allelic forms of the Plasmodium falciparum merozoite surface antigen MSA2. Mol. Biochem. Parasitol. 1990, 43, 211-220.
80. Narum, D.L.; Ogun, S.A.; Batchelor, A.H.; Holder, A.A. Passive immunization with a multicomponent vaccine against conserved domains of apical membrane antigen 1 and 235- kilodalton rhoptry proteins protects mice against Plasmodium yoelii blood-stage challenge infection. Infect Immun. 2006, 74, 5529-5536.
81. Baca, M.; Scanlan, T.; Stephenson, R.C.; Wells, J.A. Phage display of a catalytic antibody to optimize affinity for transition-state analog binding. Proc. Natl. Acad. Sci. USA 1997, 94, 10063-10068.